Compare Coursera Inc (COUR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Merck & Co., Inc. — how do they compare? Coursera Inc trades at $5.2 (market cap $1.39B), while Merck & Co., Inc. trades at $146.1 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 252.7× Coursera Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Merck & Co., Inc. for 98 Days on average.
| COUR | MRK | |
|---|---|---|
Market Cap | $1.39B | $351.28B |
Volume | 9,728,980 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $156.43 |
52-Week Low | $4.64 | $82.49 |
Typical Hold Time | 47 Days | 98 Days |
Enterprise Value | $648.49M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.235, up 2.45% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Revenue has grown steadily from $524M in 2022 to $758M in 2025, though the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights strong institutional interest, including a 137% surge in call option volume (Defense World, 2026-10-01) and the launch of Project Helix, an AI-native learning platform (Business Wire, 2026-09-09).
The stock offers upside to the $7.40 analyst consensus target but faces risks from persistent losses and integration challenges. Positive cash flow and subscriber growth are key strengths, yet profitability remains elusive. Investors should weigh the 52.94% buy rating against high RSI levels and competitive pressures in the edtech sector.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
